154 related articles for article (PubMed ID: 38049077)
101. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
102. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
103. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
104. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
105. Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: A brief landscape.
Ebrahimi S; Habibzadeh A; Khojasteh-Kaffash S; Valizadeh P; Samieefar N; Rezaei N
Crit Rev Oncol Hematol; 2024 Jan; 193():104225. PubMed ID: 38049077
[TBL] [Abstract][Full Text] [Related]
106. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
[TBL] [Abstract][Full Text] [Related]
107. Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.
Pouget JP; Chan TA; Galluzzi L; Constanzo J
Trends Cancer; 2023 Nov; 9(11):968-981. PubMed ID: 37612188
[TBL] [Abstract][Full Text] [Related]
108. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
[TBL] [Abstract][Full Text] [Related]
109. Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies.
Bilgihan MT; Eryigit AN; Ciftciler R
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):23-31. PubMed ID: 37863681
[TBL] [Abstract][Full Text] [Related]
110. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
111. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Othman T; Herrera A; Mei M
Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
[TBL] [Abstract][Full Text] [Related]
112. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
113. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management.
Ruggiero R; Di Napoli R; Balzano N; Ruggiero D; Riccardi C; Anatriello A; Cantone A; Sportiello L; Rossi F; Capuano A
Expert Rev Clin Pharmacol; 2023 May; 16(5):423-434. PubMed ID: 37144360
[TBL] [Abstract][Full Text] [Related]
114. Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer.
Wang F; Xia T; Li Z; Gao X; Fang X
Front Oncol; 2023; 13():1213297. PubMed ID: 37727216
[TBL] [Abstract][Full Text] [Related]
115. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events.
Meybodi SM; Farasati Far B; Pourmolaei A; Baradarbarjastehbaf F; Safaei M; Mohammadkhani N; Samadani AA
Med Oncol; 2023 Jul; 40(8):243. PubMed ID: 37453930
[TBL] [Abstract][Full Text] [Related]
116.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
117.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]